Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efgartigimod for perioperative myasthenia gravis (real-world observational study)
ChiCTR2600123395Phase 4Completed
- Sponsor
- The First Affiliated Hospital of Sun Yat-sen University
- Start
- Apr 2026
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efgartigimod alfa in myasthenia gravis (MG), sponsored by The First Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Quantitative Myasthenia Gravis Score and Myasthenia Gravis Activities of Daily Living Score. Started Apr 2026; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2600123395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123395.